Drug Type Autologous CAR-T |
Synonyms B7-H3/CD276 Chimeric Antigen Receptor T-Cell (Fuzhou Tcelltech Biological), TX-103-CAR-T, TX103 Chimeric Antigen Receptor T cells (Fuzhou Tcelltech Biological ) + [3] |
Target |
Mechanism CD276 inhibitors(CD276 antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
High grade glioma | Phase 1 | CN | 01 Jun 2024 | |
Recurrent Malignant Glioma | Phase 1 | CN | 01 Jun 2024 | |
WHO Grade II Glioma | Phase 1 | CN | 01 Jun 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 30 Jan 2024 | |
Malignant glioma of brain | IND Approval | US | 30 Sep 2023 |